Royalty Pharma plc (RPRX) is a publicly traded company in the Healthcare — Medical - Pharmaceuticals industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Is Royalty Pharma plc stock overvalued or undervalued in 2026?
As of October 30, 2026, Royalty Pharma plc (RPRX) trades at $67.18; its P/E is under review because the one we calculate differs from the one the data provider reports, according to Kaplio. Verdict under review: we are checking its data because the P/E we calculate differs from the one the data provider reports, and the verdict will return once they match.
Kaplio overview: Royalty Pharma plc
Market cap $30B · 52 weeks $37 – $67 (0 % below the high) · P/E under review · 2027 expected P/E 11.6× · Dividend 1.4 % · 4 years rising · Next earnings November 4, 2026 · expected EPS $1.18 · Closing price, Oct 30 · accounts published Aug 5.
- Valuation: P/E — (verdict under review).
- Business: ROIC 9 % (fair).
- Balance sheet: Net debt/EBITDA 5.1× (fragile).
- Earnings: 8 of 8 (on track).
What would it be worth at its usual multiples?
Verdict under review: we are checking its data because the P/E we calculate differs from the one the data provider reports, and the verdict will return once they match.
What matters in pharma: 3 of 6 pass
- 5y EPS growth −6.6 %, fails.
- ROIC 9.0 %, fails.
- Net debt / EBITDA 5.1×, fails.
- R&D / Revenue 19.0 %, passes.
- Gross margin 100.0 %, passes.
- FCF / Net Income 323.0 %, passes.
- P/E vs own 10y history 38.6×, info.
Against its peers (reference peers) — Royalty Pharma plc: P/E 38.6×; EV/EBITDA 22.2×; ROIC 9.0 %; $29.9B. Royal Gold, Inc. (P/E 25.0×; EV/EBITDA 16.9×; ROIC 8.6 %; $19.4B), OR Royalties Inc. (P/E 21.2×; EV/EBITDA 14.7×; ROIC 14.2 %; $6.0B), Corcept Therapeutics Incorporated (P/E 193×; EV/EBITDA —; ROIC 0.9 %; $8.8B).
Dividend
solid · Yield 1.4 % ($0.88 per share in 2025) · Years raising it 4 · paying since 2017 · 5-year growth -3 % a year · Free cash flow coverage 7.4× · With $1,000 invested today you'd collect $13.80 a year ($1.15 a month).
Profitability
| Return on Equity | 12.25% |
| Return on Invested Capital | 8.96% |
| Return on Assets | 4.11% |
| Gross Margin | 89.38% |
| Operating Margin | 62.34% |
| Net Margin | 32.15% |
Financial Health
| Debt / Equity | 1.31 |
| Current Ratio | 1.29 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 1.56 |
Price Performance
| 1 month | +16.57% |
| 3 months | +14.98% |
| Year-to-date | +73.86% |
| 1 year | +78.96% |
| 3 years | +146.71% |
| 5 years | +69.09% |
Dividend History
Paid in the last 12 months: $0.9250 per share in 4 payments.
| Date | Amount |
|---|---|
| 2026-11-13 | $0.2350 |
| 2026-08-14 | $0.2350 |
| 2026-05-15 | $0.2350 |
| 2026-02-20 | $0.2350 |
| 2025-11-14 | $0.2200 |
| 2025-08-15 | $0.2200 |
| 2025-05-16 | $0.2200 |
| 2025-02-21 | $0.2200 |
| 2024-11-15 | $0.2100 |
| 2024-08-16 | $0.2100 |
Amounts adjusted for stock splits.
Related companies: RGLD · OR · 0I3Q.L · CORT · KNSA · 0HF9.L · LQDA · PBH
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of RPRX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks